AMLX FY 2025 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$153M

Net Income

-$145M

EPS (Diluted)

$-1.53

Cash Flow

Operating Cash Flow

-$123M

Free Cash Flow

-$123M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$333M

Total Liabilities

$27M

Stockholders' Equity

$305M

Cash & Equivalents

$227M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$87M	-100.0%
Gross Profit	$0	$45M	-100.0%
Operating Income	-$153M	-$315M	+51.3%
Net Income	-$145M	-$302M	+52.0%